Format

Send to

Choose Destination
Nat Rev Neurol. 2011 Sep 27;7(11):650-4. doi: 10.1038/nrneurol.2011.147.

How can we improve clinical trials in amyotrophic lateral sclerosis?

Author information

1
Département des Maladies du Système Nerveux, Assistance Publique-Hôpitaux de Paris, Hôpital de la Salpétrière, 47 Boulevard de l’Hôpital, 75013 Paris, France.

Abstract

Since the approval of riluzole for the treatment of amyotrophic lateral sclerosis (ALS) 17 years ago, more than 30 large clinical trials have been conducted, but none has proved successful. The failure to translate positive preclinical results into the clinical setting raises questions about the validity of the rodent model that is used to study ALS, and about the quality of both preclinical and clinical studies. However, the greatest challenge is the disease itself as, with rare exceptions, the causes are unknown. In this Perspectives article, we highlight key issues related to the pathophysiology, preclinical studies and clinical trials that should be addressed in the future. These areas include the relationships between different disease mechanisms, the challenges presented by the heterogeneity of the disease, and the need for early intervention, optimal dose selection and effective biomarkers.

PMID:
21947135
DOI:
10.1038/nrneurol.2011.147
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center